



1 Feb
1614

PATENT
Atty. Docket No. 19016.0003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stephen D. Harrison et al.

Serial No.: 10/506,570

Group Art Unit:

Filed: April 29, 2005

Examiner: to be assigned

For: METHODS AND COMPOSITIONS FOR TREATMENT OF ISCHEMIA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 AND §1.97(b)(3)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The citations listed on the enclosed Supplemental Information Disclosure Form PTO-1449 may be material to the examination of the above-identified patent application. Therefore, Applicants submit these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(b)(3). The Examiner is requested to make these citations of official record in the present application.


This Supplemental Information Disclosure Statement under 37 CFR §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this citation constitutes prior art under 35 USC §102 or §103.

I hereby certify that this correspondence is being deposited
with the United States Postal Service as First Class mail in
an envelope addressed to: Mail Stop _____,
Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450.
on this 11 day of May, 2006.
By [Signature]

The present Supplemental Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

The Commissioner is hereby authorized to charge any fees in connection with this Information Disclosure Statement to Deposit Account No. 03-1664.

Respectfully submitted,

By: 

Young J. Suh
Attorney for Applicants
Reg. No. 41,337

May 11, 2006

~~March 3, 2003~~

CHIRON CORPORATION
Intellectual Property - R440
P.O. Box 8097
Emeryville, California 94662-8097
(510) 923-2706
(510) 655-3542 (fax)



SHEET 1 OF 1

FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 19016.0003	Serial No.: 10/506,570
INFORMATION DISCLOSURE CITATION		Applicants: Harrison <u>et al.</u>	
(Use several sheets if necessary)		Filing Date: April 29, 2005	Group: 1614

U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Publ. Date	Country	Class	Subclass	Trans- Yes	lation No
BA							

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Dale "Signal Transduction by the Wnt Family of Ligands" <u>Biochemical J.</u> 329:209-223, 1998
CB	Gottron <u>et al.</u> , "Caspase Inhibition Selectively Reduces the Apoptotic Component of Oxygen-Glucose Deprivation-Induced Cortical Neuronal Cell Death" <u>Molecular and Cellular Neurosciences</u> 9:159-169, 1997
CC	Himi <u>et al.</u> , "A Caspase Inhibitor Blocks Ischaemia-Induced Delayed Neuronal Death in the Gerbil" <u>European Journal Neuroscience</u> 10:777-781, 1998
CD	Lawrence <u>et al.</u> , "Overexpression of Bcl-2 with Herpes Simplex Virus Vectors Protects CNS Neurons Against Neurological Insults <i>In Vitro</i> and <i>In Vivo</i> " <u>Journal Neuroscience</u> 16(2):486-496, January, 1996
CE	Lawrence <u>et al.</u> , "Herpes Simplex Viral Vectors Expressing Bcl-2 are Neuroprotective When Delivered After a Stroke" <u>J. Cerebral Blood Flow and Metabolism</u> 17:740-744, 1997
CF	Maier <u>et al.</u> , "Optimal Depth and Duration of Mild Hypothermia in a Focal Model of Transient Cerebral Ischemia" <u>Stroke</u> 29:2171-2180, 1998
CG	Namura <u>et al.</u> , "Activation and Cleavage of Caspase-3 in Apoptosis Induced by Experimental Cerebral Ischemia" <u>J. Neuroscience</u> 18(10):3659-3668, 1998
CH	Pap <u>et al.</u> , "Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway" <u>J. Biological Chemistry</u> 273(32):19929-19932, 1998
CI	Takashima <u>et al.</u> , "Presenilin 1 Associates with Glycogen Synthase Kinase-3beta and its Substrate tau" <u>Proc. Natl. Acad. Sci.</u> 95:9637-9641, August, 1998
CJ	Yenari <u>et al.</u> , "Time-Course and Treatment Response with SNX-111, an N-type Calcium Channel Blocker, in a Rodent Model of Focal Cerebral Ischemia Using Diffusion-Weighted MRI" <u>Brain Research</u> 739:36-45, 1996
CK	Zhang <u>et al.</u> , "Destabilization of B-Catenin by Mutations in Presenilin-1 Potentiates Neuronal Apoptosis" 395:698-702, October, 1998
Examiner	
Date Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.